SCHEMBL580810

SCHEMBL580810

COC(=O)N1CCC(CO)CC1Cc1ccc(C(C)(C)C)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2B Q13224 1/20 0.41
KCNH2 Q12809 1/20 0.40
CACNA1I Q9P0X4 1/20 0.40
CYP3A4 P08684 3/20 0.39
CYP2D6 P10635 1/20 0.37
CYP2C19 P33261 1/20 0.37
NPC1 O15118 2/20 0.37
RAB9A P51151 2/20 0.37
TACR1 P25103 1/20 0.36
CHRM3 P20309 1/20 0.36
PSEN1 P49768 1/20 0.35
PSEN2 P49810 1/20 0.35
APH1B Q8WW43 1/20 0.35
NCSTN Q92542 1/20 0.35
APH1A Q96BI3 1/20 0.35
PSENEN Q9NZ42 1/20 0.35
MEN1 O00255 5/20 0.35
KMT2A Q03164 5/20 0.35
ALDH1A1 P00352 2/20 0.35
KDM4E B2RXH2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL581881 0.84 GRIN2B (0.39) GRIN2BKCNH2CACNA1ICYP3A4CYP2D6
SCHEMBL581238 0.84 NPC1 (0.41) GRIN2BCYP3A4CYP2D6CYP2C19NPC1
SCHEMBL582047 0.78 MEN1 (0.42) GRIN2BCYP3A4CYP2C19NPC1RAB9A
SCHEMBL3073122 0.78 MEN1 (0.42) GRIN2BCYP3A4CYP2C19NPC1RAB9A
SCHEMBL582515 0.78 MEN1 (0.42) GRIN2BCYP3A4CYP2C19NPC1RAB9A
SCHEMBL581806 0.77 BRD4 (0.38) CHRM3PSEN1PSEN2APH1BNCSTN
SCHEMBL580875 0.76 NR1H2 (0.35)
SCHEMBL586823 0.76 TACR1 (0.44) KCNH2CYP3A4TACR1KMT2AALDH1A1
SCHEMBL580880 0.76 PLG (0.41) CYP3A4CYP2D6CYP2C19NPC1RAB9A
SCHEMBL581973 0.76 PLG (0.41) CYP3A4CYP2D6CYP2C19NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8415378-B2 Isoxazol-3(2H)-one analogs as therapeutic agents ASTRAZENECA AB (SE) 2013-04-09 US disclosed
EP-2417131-A1 ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS AstraZeneca AB (SE) 2012-02-15 EP disclosed
WO-2010117323-A1 METHOD AND APPARATUS FOR PRODUCING HEAT ENERGY AND CARBON DIOXIDE ASTRAZENECA AB (SE) 2010-10-14 WO disclosed
US-20100261755-A1 ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS ASTRAZENECA AB (SE) 2010-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261755-A1 ISOXAZOL-3(2H)-ONE ANALOGS AS THERAPEUTIC AGENTS NR4A3, CBR3, OXER1 GRIN2B 1465/4885KCNH2 1302/4885CACNA1I 2638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.